Tirzepatide leads to greater weight loss than semaglutide in adults with obesity but without type 2 diabetes, a head-to-head trial suggests. Published in the New…
A retrospective cohort study has linked semaglutide to double the risk of serious optic neuropathy in type 2 diabetes patients. Published in JAMA Ophthalmology, the…
Semaglutide is a game changer for patients right up until they stop the treatment, when many face the heartbreak of watching the kilos return. That…
The TGA has approved Wegovy to reduce the risk of major adverse events in patients with cardiovascular disease who are overweight or obese. The once-weekly…
A case series has rekindled concerns about potential eye-related complications associated with semaglutide and tirzepatide. Published in JAMA Ophthalmology, it documents instances of serious ophthalmic…
A major study of nearly two million patients with type 2 diabetes has highlighted the potential wide-ranging health benefits of GLP-1 receptor agonists — but…
GLP-1 receptor agonists offer significant renal protection as well as cardiovascular benefits, a meta-analysis shows. Australian-led research has found that patients taking the drugs have…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.
